Upon inquiring for potential genes contributing to cisplatin resistance due to MECOM amplification, we identified transcription co-activator SUB1, a proposed carcinogenic gene implicated in hepatoblastoma malignancy [75] and associated with poor prognosis in breast cancer metastasis [76]. Here, MECOM is linked to breast carcinoma.